Anti-IL17A Antibody-Cytokine Fusion Protein, IgG (Vunakizumab)-IL22 (CAT#: VS-0624-FY84)

• Target
• IL-17A

• Molecule Class
• IgG-IL22

• Species Reactivity
• Human

• Clone
• Vunakizumab

• Related Disease
• Inflammatory bowel diseases

• Cytokine 1
• IL22

• Cytokines 1 Description
• IL-22 is an alpha-helical cytokine. IL-22 binds to a heterodimeric cell surface receptor composed of IL-10R2 and IL-22R1 subunits. IL-22R is expressed on tissue cells and absent on immune cells.
  Crystallization was possible if the N-linked glycosylation site was removed in an IL-22 mutant that binds to the high-affinity cell surface receptor sIL-22R1. The crystal asymmetric unit contains two IL-22-sIL-22R1 complexes.

• Cytokine 1 Species
• Mouse

• Applications
• This product is for immuno therapy research. It can be used therapeutically to deliver biologically active ligands to a desired tissue.

• Introduction
• The protein encoded by this gene is a proinflammatory cytokine produced by activated T cells. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

• Alternative Names
• Interleukin 17A; vmab-mIL22

• Gene ID
• 3605

• UniProt ID
• Q16552

Select a product category from the dropdown menu below to view related products.